August 6, 2020 — Fort Lauderdale, FL – Green Point Research (GPR), the corporate parent and distributor of Satividol, a premium hemp-derived CBD (cannabidiol) brand, has announced its newest product: Satividol Roll-On CBD Relief (500 MG). The extreme popularity of the CBD prompted the creation of an official annual calendar event for National CBD Day in 2018. In 2019, the company celebrated by providing a local Fort Lauderdale ice cream shop with hemp-derived CBD for the special occasion. The 2020 CBD Day is being celebrated with its new product announcement.
Satividol’s newest product contains a proprietary blend of premium hemp-derived CBD, aloe vera, vitamin E, rosemary, menthol, and camphor oil. With a refreshing minty smell, the topical rolls right onto the skin, providing an instant cooling feeling, and can be an effective solution for many seeking relief from various wellness challenges. The roll-on’s nano-emulsified technology increases the absorption of active ingredients during the application, aiding in faster penetration, duration of action, and bioavailability of the product.
David Hasenauer, CEO of Green Point Research, shares, “We aim to bring quality wellness products to market through our Satividol consumer brand while promoting sustainable agriculture and supporting the American farmer.”
“The positive customer feedback from our softgel product and their heightened recent interest in additional CBD solutions led to the expansion of our product offerings to include a roll-on topical product,” said Robin Parton Pate, CMO of Green Point Research. “Consumers are driving significant increases in demand for new CBD products across the world, and we believe the pharmacist-formulated, Satividol Roll-On CBD Relief (500 MG) with nano-emulsified technology will provide an everyday solution to many common wellness challenges.”
Cannabidiol, commonly known as CBD, is a compound found in the hemp plant, and its effectiveness can depend on the source, quality, and dosage. Green Point Research ensures a complete chain of custody control on Satividol products through its U.S.-based farm operations to guarantee the full potential of hemp. GPR’s vertical integration allows oversight during seed creation, harvesting, processing, extraction, manufacturing and packaging, all the way until the bottle is sealed and shipped to the end consumer. In addition, each bottle proudly displays a QR code link to the certificate of analysis associated with the specific batch of CBD isolate utilized in the production of the roll-on.
Satividol is currently under a clinical trial in partnership with Florida State University, a public university. Through this research, the economic and medicinal value of Cannabidiol (CBD) is being assessed. The research comparing Satividol’s analgesic benefits to acute pain has received mainstream media attention from the Miami Herald and others asking the question, “Is CBD the next ibuprofen?”
According to Allied Market Research, the global CBD skincare market is anticipated to reach $3.4 billion by 2026. Wellness market projections are even higher. With the significant attention being focused on CBD research yielding impressive results, especially by companies such as Green Point Research, the consumer adoption of CBD solutions and overall CBD market share in the wellness category are both expected to grow.
About Green Point Research
Green Point Research (GPR) is a vertically integrated phytocannabinoid-rich biomass originator and processor founded in 2016. GPR controls its supply chain from seed to processing bulk cannabinoids for business to business sale. The Satividol, cannabidiol (CBD) brand, managed and distributed by Green Point Research, is among the brands the company manages. Contact Green Point Research at 954-500-HEMP to learn more about the biotechnology company and its Satividol products. For more information, please visit www.satividol.com or www.greenpointresearch.com.